The peptide hemopressin acts through CB1 cannabinoid receptors to reduce food intake in rats and mice

Journal of Neuroscience

Volumn 30, Issue 21, 2010, Pages 7369-7376

  Dodd, Garron T ^a   Mancini, Giacomo ^b   Lutz, Beat ^b   Luckman, Simon M ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

4 (1,1 DIMETHYLHEPTYL) 1',2',3',4',5',6' HEXAHYDRO 2,3' DIHYDROXY 6' (3 HYDROXYPROPYL)BIPHENYL; CANNABINOID 1 RECEPTOR; HEMOPRESSIN; PEPTIDE; UNCLASSIFIED DRUG;

ANIMAL CELL; APPETITE; ARTICLE; CONTROLLED STUDY; FOOD INTAKE; HYPERPHAGIA; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; RAT; REFEEDING; SATIETY; SIGNAL TRANSDUCTION;

ANALYSIS OF VARIANCE; ANIMALS; BEHAVIOR, ANIMAL; BENZOXAZINES; CERCOPITHECUS AETHIOPS; CIRCADIAN RHYTHM; COS CELLS; CYCLOHEXANOLS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRINKING BEHAVIOR; DRUG ADMINISTRATION ROUTES; EATING; FOOD DEPRIVATION; GREEN FLUORESCENT PROTEINS; HEMOGLOBINS; HYPERPHAGIA; LEPTIN; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MORPHOLINES; NAPHTHALENES; PEPTIDE FRAGMENTS; PIPERIDINES; PROTEIN TRANSPORT; PSYCHOTROPIC DRUGS; PYRAZOLES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR, CANNABINOID, CB1; TETRAHYDROCANNABINOL; TIME FACTORS; TRANSFECTION;

EID: 77953074998     PISSN: 02706474     EISSN: 15292401     Source Type: Journal    
DOI: 10.1523/JNEUROSCI.5455-09.2010     Document Type: Article

References (57)

1. Arnone M, Maruani J, Chaperon F, Thiébot MH, Poncelet M, Soubrié P, Le Fur G (1997) Selective inhibition of sucrose and ethanol intake by SR 141716, an antagonist of central cannabinoid (CB1) receptors. Psychopharmacology (Berl) 132:104-106. (Pubitemid 27303746)
2. Bisogno T (2008) Endogenous cannabinoids: structure and metabolism. J Neuroendocrinol 20 [Suppl 1]:1-9.
3. Blair RE, Deshpande LS, Sombati S, Elphick MR, Martin BR, DeLorenzo RJ (2009) Prolonged exposure to WIN55,212-2 causes downregulation of the CB1 receptor and the development of tolerance to its anticonvulsant effects in the hippocampal neuronal culture model of acquired epilepsy. Neuropharmacology 57:208-218.
4. Christensen R, Kristensen PK, Bartels EM, Bliddal H, Astrup A (2007) Efficacy and safety of the weight-loss drug rimonabant: a meta-analysis of randomised trials. Lancet 370:1706-1713. (Pubitemid 350100788)
5. Colombo G, Agabio R, Diaz G, Lobina C, Reali R, Gessa GL (1998) Appetite suppression and weight loss after the cannabinoid antagonist SR 141716. Life Sci 63:PL113-PL117.
6. Cota D, Marsicano G, Lutz B, Vicennati V, Stalla GK, Pasquali R, Pagotto U (2003a) Endogenous cannabinoid system as a modulator of food intake. Int J Obes Relat Metab Disord 27:289-301.
7. Cota D, Marsicano G, Tschöp M, Grübler Y, Flachskamm C, Schubert M, Auer D, Yassouridis A, Thöne-Reineke C, Ortmann S, Tomassoni F, Cervino C, Nisoli E, Linthorst AC, Pasquali R, Lutz B, Stalla GK, Pagotto U (2003b) The endogenous cannabinoid system affects energy balance via central orexigenic drive and peripheral lipogenesis. J Clin Invest 112:423-431.
8. Cota D, Tschöp MH, Horvath TL, Levine AS (2006) Cannabinoids, opioids and eating behavior: the molecular face of hedonism? Brain Res Rev 51:85-107.
9. Coutts AA, Anavi-Goffer S, Ross RA, MacEwan DJ, Mackie K, Pertwee RG, Irving AJ (2001) Agonist-induced internalization and trafficking of cannabinoid CB1 receptors in hippocampal neurons. J Neurosci 21:2425-2433. (Pubitemid 32240539)
10. Daigle TL, Kearn CS, Mackie K (2008) Rapid CB1 cannabinoid receptor desensitization defines the time course of ERK1/2 MAP kinase signaling. Neuropharmacology 54:36-44.
11. Dale CS, Pagano Rde L, Rioli V, Hyslop S, Giorgi R, Ferro ES (2005) Antinociceptive action of hemopressin in experimental hyperalgesia. Peptides 26:431-436. (Pubitemid 40126700)
12. Di Marzo V (2008) The endocannabinoid system in obesity and type 2 diabetes. Diabetologia 51:1356-1367.
13. Di Marzo V, Goparaju SK, Wang L, Liu J, Bátkai S, Járai Z, Fezza F, Miura GI, Palmiter RD, Sugiura T, Kunos G (2001) Leptin-regulated endocannabinoids are involved in maintaining food intake. Nature 410:822-825. (Pubitemid 32303781)
14. Dodd GT, Stark JA, McKie S, Williams SR, Luckman SM (2009) Central cannabinoid signaling mediating food intake: a pharmacological-challenge magnetic resonance imaging and functional histology study in rat. Neuroscience 163:1192-1200.
15. Gomes I, Grushko JS, Golebiewska U, Hoogendoorn S, Gupta A, Heimann AS, Ferro ES, Scarlata S, Fricker LD, Devi LA (2009) Novel endogenous peptide agonists of cannabinoid receptors. FASEB J 23:3020-3029.
16. Gómez R, Navarro M, Ferrer B, Trigo JM, Bilbao A, Del Arco I, Cippitelli A, Nava F, Piomelli D, Rodríguez de Fonseca F (2002) A peripheral mechanism for CB1 cannabinoid receptor-dependent modulation of feeding. J Neurosci 22:9612-9617.
17. Halford JC, Wanninayake SC, Blundell JE (1998) Behavioral satiety sequence (BSS) for the diagnosis of drug action on food intake. Pharmacol Biochem Behav 61:159-168.
18. Hao S, Avraham Y, Mechoulam R, Berry EM (2000) Low dose anandamide affects food intake, cognitive function, neurotransmitter and corticosterone levels in diet-restricted mice. Eur J Pharmacol 392:147-156. (Pubitemid 30184903)
19. Heimann AS, Gomes I, Dale CS, Pagano RL, Gupta A, de Souza LL, Luchessi AD, Castro LM, Giorgi R, Rioli V, Ferro ES, Devi LA (2007) Hemopressin is an inverse agonist of CB1 cannabinoid receptors. Proc Natl Acad Sci U S A 104:20588-20593.
20. Hsieh C, Brown S, Derleth C, Mackie K (1999) Internalization and recycling of the CB1 cannabinoid receptor. J Neurochem 73:493-501. (Pubitemid 29339821)
21. Jamshidi N, Taylor DA (2001) Anandamide administration into the ventromedial hypothalamus stimulates appetite in rats. Br J Pharmacol 134:1151-1154.
22. Kano M, Ohno-Shosaku T, Hashimotodani Y, Uchigashima M, Watanabe M (2009) Endocannabinoid-mediated control of synaptic transmission. Physiol Rev 89:309-380.
23. Kirkham TC (2009) Cannabinoids and appetite: food craving and food pleasure. Int Rev Psychiatry 21:163-171.
24. Kirkham TC, Williams CM, Fezza F, Di Marzo V (2002) Endocannabinoid levels in rat limbic forebrain and hypothalamus in relation to fasting, feeding and satiation: stimulation of eating by 2-arachidonoyl glycerol. Br J Pharmacol 136:550-557.
25. Kunos G, Osei-Hyiaman D, Bátkai S, Sharkey KA, Makriyannis A (2009) Should peripheral CB(1) cannabinoid receptors be selectively targeted for therapeutic gain? Trends Pharmacol Sci 30:1-7.
26. Lawrence CB, Ellacott KL, Luckman SM (2002) PRL-releasing peptide reduces food intake and may mediate satiety signaling. Endocrinology 143:360-367.
27. Lippton H, Lin B, Gumusel B, Witriol N, Wasserman A, Knight M (2006) Hemopressin, a hemoglobin fragment, dilates the rat systemic vascular bed through release of nitric oxide. Peptides 27:2284-2288. (Pubitemid 44189636)
28. Lu D, Willard D, Patel IR, Kadwell S, Overton L, Kost T, Luther M, Chen W, Woychik RP, Wilkison WO, Cone RD (1994) Agouti protein is an antagonist of the melanocyte-stimulating-hormone receptor. Nature 371:799-802. (Pubitemid 24333868)
29. Marsicano G, Wotjak CT, Azad SC, Bisogno T, Rammes G, Cascio MG, Hermann H, Tang J, Hofmann C, Zieglgänsberger W, Di Marzo V, Lutz B (2002) The endogenous cannabinoid system controls extinction of aversive memories. Nature 418:530-534. (Pubitemid 34851398)
30. Nissen SE, Nicholls SJ, Wolski K, Rodés-Cabau J, Cannon CP, Deanfield JE, Despres JP, Kastelein JJ, Steinhubl SR, Kapadia S, Yasin M, Ruzyllo W, Gaudin C, Job B, Hu B, Bhatt DL, Lincoff AM, Tuzcu EM (2008) Effect of rimonabant on progression of atherosclerosis in patients with abdominal obesity and coronary artery disease: the STRADIVARIUS randomized controlled trial. JAMA 299:1547-1560.
31. Nogueiras R, Veyrat-Durebex C, Suchanek PM, Klein M, Tschöp J, Caldwell C, Woods SC, Wittmann G, Watanabe M, Liposits Z, Fekete C, Reizes O, Rohner-Jeanrenaud F, Tschöp MH (2008) Peripheral, but not central, CB1 antagonism provides food intake-independent metabolic benefits in diet-induced obese rats. Diabetes 57:2977-2991.
32. Nyberg F, Sanderson K, Glämsta EL (1997) The hemorphins: a new class of opioid peptides derived from the blood protein hemoglobin. Biopolymers 43:147-156. (Pubitemid 27291394)
33. Ollmann MM, Wilson BD, Yang YK, Kerns JA, Chen Y, Gantz I, Barsh GS (1997) Antagonism of central melanocortin receptors in vitro and in vivo by agouti-related protein. Science 278:135-138.
34. Pagotto U, Marsicano G, Cota D, Lutz B, Pasquali R (2006) The emerging role of the endocannabinoid system in endocrine regulation and energy balance. Endocr Rev 27:73-100.
35. Paxinos G, Watson C (1998) The rat brain in stereotaxic coordinates, Ed 4. San Diego: Academic.
36. Petrosino S, Ligresti A, Di Marzo V (2009) Endocannabinoid chemical biology: a tool for the development of novel therapies. Curr Opin Chem Biol 13:309-320.
37. Pritchard LE, Armstrong D, Davies N, Oliver RL, Schmitz CA, Brennand JC, Wilkinson GF, White A (2004) Agouti-related protein (83-132) is a competitive antagonist at the human melanocortin-4 receptor: no evidence for differential interactions with pro-opiomelanocortin-derived ligands. J Endocrinol 180:183-191.
38. Richter F, Meurers BH, Zhu C, Medvedeva VP, Chesselet MF (2009) Neurons express hemoglobin alpha- and beta-chains in rat and human brains. J Comp Neurol 515:538-547.
39. Rioli V, Gozzo FC, Heimann AS, Linardi A, Krieger JE, Shida CS, Almeida PC, Hyslop S, Eberlin MN, Ferro ES (2003) Novel natural peptide substrates for endopeptidase 24.15, neurolysin, and angiotensin-converting enzyme. J Biol Chem 278:8547-8555.
40. Rowland NE, Mukherjee M, Robertson K (2001) Effects of the cannabinoid receptor antagonist SR 141716, alone and in combination with dexfenfluramine or naloxone, on food intake in rats. Psychopharmacology (Berl) 159:111-116.
41. Schelshorn DW, Schneider A, Kuschinsky W, Weber D, Krüger C, Dittgen T, Bürgers HF, Sabouri F, Gassler N, Bach A, Maurer MH (2009) Expression of hemoglobin in rodent neurons. J Cereb Blood Flow Metab 29:585-595.
42. Scott V, Kimura N, Stark JA, Luckman SM (2005) Intravenous peptide YY3-36 and Y2 receptor antagonism in the rat: effects on feeding behaviour. J Neuroendocrinol 17:452-457.
43. Simi A, Lerouet D, Pinteaux E, Brough D (2007) Mechanisms of regulation for interleukin-1beta in neurodegenerative disease. Neuropharmacology 52:1563-1569.
44. Simiand J, Keane M, Keane PE, Soubrié P (1998) SR 141716, a CB1 cannabinoid receptor antagonist, selectively reduces sweet food intake in marmoset. Behav Pharmacol 9:179-181.
45. Soria-Gómez E, Matias I, Rueda-Orozco PE, Cisneros M, Petrosino S, Navarro L, Di Marzo V, Prospéro-García O (2007) Pharmacological enhancement of the endocannabinoid system in the nucleus accumbens shell stimulates food intake and increases c-Fos expression in the hypothalamus. Br J Pharmacol 151:1109-1116.
46. Svízenská I, Dubový P, Sulcová A (2008) Cannabinoid receptors 1 and 2 (CB1 and CB2), their distribution, ligands and functional involvement in nervous system structures - a short review. Pharmacol Biochem Behav 90:501-511.
47. Tallett AJ, Blundell JE, Rodgers RJ (2007a) Grooming, scratching and feeding: role of response competition in acute anorectic response to rimonabant in male rats. Psychopharmacology (Berl) 195:27-39.
48. Tallett AJ, Blundell JE, Rodgers JR (2007b) Acute anorectic response to cannabinoid CB1 receptor antagonist/inverse agonist AM251 in rats: indirect behavioural mediation. Behav Pharmacol 18:591-600.
49. Tallett AJ, Blundell JE, Rodgers RJ (2008) Endogenous opioids and cannabinoids: system interactions in the regulation of appetite, grooming and scratching. Physiol Behav 94:422-431.
50. Van Gaal LF, Rissanen AM, Scheen AJ, Ziegler O, Rössner S (2005) Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study. Lancet 365:1389-1397. (Pubitemid 40523733)
51. Verty AN, McFarlane JR, McGregor IS, Mallet PE (2004a) Evidence for an interaction between CB1 cannabinoid and oxytocin receptors in food and water intake. Neuropharmacology 47:593-603.
52. Verty AN, McFarlane JR, McGregor IS, Mallet PE (2004b) Evidence for an interaction between CB1 cannabinoid and melanocortin MCR-4 receptors in regulating food intake. Endocrinology 145:3224-3231.
53. Verty AN, McGregor IS, Mallet PE (2005) Paraventricular hypothalamic CB(1) cannabinoid receptors are involved in the feeding stimulatory effects of Delta(9)-tetrahydrocannabinol. Neuropharmacology 49:1101-1109.
54. Ward SJ, Dykstra LA (2005) The role of CB1 receptors in sweet versus fat reinforcement: effect of CB1 receptor deletion, CB1 receptor antagonism (SR141716A) and CB1 receptor agonism (CP-55940). Behav Pharmacol 16:381-388.
55. Werner NA, Koch JE (2003) Effects of the cannabinoid antagonists AM281 and AM630 on deprivation-induced intake in Lewis rats. Brain Res 967:290-292.
56. Williams CM, Kirkham TC (1999) Anandamide induces overeating: mediation by central cannabinoid (CB1) receptors. Psychopharmacology (Berl) 143:315-317.
57. Williams CM, Kirkham TC (2002) Reversal of delta 9-THC hyperphagia by SR141716 and naloxone but not dexfenfluramine. Pharmacol Biochem Behav 71:333-340.